Psychiatr. praxi. 2016;17(2):65-68 | DOI: 10.36290/psy.2016.017

Aripiprazole in the treatment of schizophrenia – its use in clinical practice

MUDr. Sylva Racková, Ph.D.
Psychiatrická ambulance, Plzeň
Psychiatrická klinika 1. LF UK a VFN, Praha

There are available many types of antipsychotics in recent days. Aripiprazole is a partial agonist of D2 and 5-HT1A and antagonist of 5-HT2A receptors. It belongs among antipsychotics with low occurrence of averse events, especially metabolic like increase body weight, prolactine level. We demonstrate on 3 case reports of schizophenic patients when is possible to use aripiprazole in their treatment.

Keywords: aripiprazole, schizophrenia, efficacy, tollerability, augmentation, atypic antipsychotics

Published: June 10, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S. Aripiprazole in the treatment of schizophrenia – its use in clinical practice. Psychiatr. praxi. 2016;17(2):65-68. doi: 10.36290/psy.2016.017.
Download citation

References

  1. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder, Neuropsychiatric Disease and Treatment 2006; 2(4) 427-443. Go to original source... Go to PubMed...
  2. European Medicines Agency, www.ema.europa.eu. Aripiprazol, poslední revize 21. 04. 2016
  3. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056. Go to original source... Go to PubMed...
  4. Meng M, Li W, Zhang S, Wang H, Sheng J, Wang J, Li C. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27(1): 4-17.
  5. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9(4): e94112. Go to original source... Go to PubMed...
  6. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014; 2(1): CD006569. Go to original source...
  7. Charpeaud T, Samalin L, Llorca PM. Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required? Encephale 2014; 40(1): 62-73. Go to original source... Go to PubMed...
  8. Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res 2015; 62: 38-47. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.